Circulating Tumor DNA as a Marker of Minimal Residual Disease
Cancer Network,
Ben Fangman, MD, and colleagues provide an overview of the use of circulating tumor DNA levels to detect minimal residual…
Ben Fangman, MD, and colleagues provide an overview of the use of circulating tumor DNA levels to detect minimal residual…
Serial postoperative ctDNA analysis could be a useful tool in guiding treatment decisions and improving care for patients with…
Immunotherapy using checkpoint inhibitors can work well to treat cancer, but only a minority of patients respond to therapy.
Immunotherapy using checkpoint inhibitors can work well to treat cancer, but only a minority of patients respond to therapy.
Immunotherapy using checkpoint inhibitors can work well to treat cancer, but only a minority of patients respond to therapy.
image: Ben Larimer view more BIRMINGHAM, Ala. – Immunotherapy using checkpoint inhibitors can work well to treat cancer, but…
BIRMINGHAM, Ala. – Immunotherapy using checkpoint inhibitors can work well to treat cancer, but only a minority of patients…
Key clinical point: The assessment of circulating tumor DNA (ctDNA) performed postoperatively, postadjuvantly, and serially…
NEW YORK – Natera highlighted the publication of new data this week demonstrating that its personalized, tumor-informed…
NEW YORK – Natera highlighted the publication of new data this week demonstrating that its personalized, tumor-informed…
Peer-reviewed study in stage III colorectal cancer demonstrates the prognostic value of ctDNA growth rate as measured by…
Peer-reviewed study in stage III colorectal cancer demonstrates the prognostic value of ctDNA growth rate as measured by…
Peer-reviewed study in stage III colorectal cancer demonstrates the prognostic value of ctDNA growth rate as measured by…
Peer-reviewed study in stage III colorectal cancer demonstrates the prognostic value of ctDNA growth rate as measured by…
AUSTIN, Texas, Oct. 11, 2021 /PRNewswire/ -- (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA…
AUSTIN, Texas, Oct. 11, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell…
AUSTIN, Texas, Oct. 11, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell…
Natera Announces New Publication Validating Signatera® Velocity Metric to Improve Cancer Management Peer-reviewed study in…
AUSTIN, Texas, Oct. 11, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell…
Peer-reviewed study in stage III colorectal cancer demonstrates the prognostic value of ctDNA growth rate as measured by…
Peer-reviewed study in stage III colorectal cancer demonstrates the prognostic value of ctDNA growth rate as measured by…
Peer-reviewed study in stage III colorectal cancer demonstrates the prognostic value of ctDNA growth rate as measured by…
AUSTIN, Texas, Oct. 11, 2021 /PRNewswire/ -- (NASDAQ:), a leader in transforming care through genetic and cell-free DNA testing…
Peer-reviewed study in stage III colorectal cancer demonstrates the prognostic value of ctDNA growth rate as measured by…